Patent intelligence · US
US 8431154
Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Patent details — US 8431154
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 30, 2013
- Expiration
- Apr 25, 2033
- Applicant
- TAKEDA GMBH
- Claims
- 38
- CPC classes
- A61K, A61K31/166, A61K31/44, A61K9/0002
Quick answer
US 8431154 (Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient) is held by TAKEDA GMBH. Status: granted. Granted Apr 30, 2013. Expires Apr 25, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TAKEDA GMBH
- Grant date
- Expiration
- Claims
- 38
- CPC classes
- A61K, A61K31/166, A61K31/44, A61K9/0002, A61K9/0053, A61K9/20
More from TAKEDA GMBH
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 8431154?
US 8431154 (Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient) is held by TAKEDA GMBH. Status: granted. Granted Apr 30, 2013. Expires Apr 25, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8431154?
TAKEDA GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 8431154 expire?
Our index shows an expiration date of Apr 25, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.